NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ionis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $53.34 -0.76 (-1.40 %) (As of 08/11/2020 02:17 PM ET) Add Compare Share Today's Range$51.80Now: $53.34▼$53.6450-Day Range$54.10MA: $59.76▼$62.9552-Week Range$39.32Now: $53.34▼$73.09Volume24,555 shsAverage Volume669,739 shsMarket Capitalization$7.45 billionP/E Ratio60.61Dividend YieldN/ABeta1.61 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 8 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.85, Ionis Pharmaceuticals has a potential upside of 40.2% from its current price of $53.38.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesIonis Pharmaceuticals has received 630 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIonis Pharmaceuticals has received 747 “underperform” votes. (Add your “underperform” vote.)Community SentimentIonis Pharmaceuticals has received 54.25% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote “Outperform” if you believe IONS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,123,750.00 in company stock.Percentage Held by InsidersOnly 2.67% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions84.04% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($0.51) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is 60.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is 60.66, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.34.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone760-931-9200Debt Debt-to-Equity Ratio0.50 Current Ratio10.94 Quick Ratio10.84Price-To-Earnings Trailing P/E Ratio60.61 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 billion Price / Sales6.64 Cash Flow$2.31 per share Price / Cash Flow23.13 Book Value$11.98 per share Price / Book4.45Profitability EPS (Most Recent Fiscal Year)$2.08 Net Income$303.26 million Net Margins13.81% Return on Equity10.27% Return on Assets5.30%Miscellaneous Employees737 Outstanding Shares139,700,000Market Cap$7.45 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $53.34 -0.76 (-1.40 %) (As of 08/11/2020 02:17 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions How has Ionis Pharmaceuticals' stock price been impacted by COVID-19? Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS shares have increased by 8.5% and is now trading at $53.34. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ionis Pharmaceuticals. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Ionis Pharmaceuticals. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.05. The business earned $146 million during the quarter, compared to the consensus estimate of $148.87 million. Ionis Pharmaceuticals had a net margin of 13.81% and a return on equity of 10.27%. The company's revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.01) earnings per share. View Ionis Pharmaceuticals' earnings history. What price target have analysts set for IONS? 15 Wall Street analysts have issued 1-year target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $54.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $74.85 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals. Has Ionis Pharmaceuticals been receiving favorable news coverage? Media stories about IONS stock have trended neutral recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Ionis Pharmaceuticals. Are investors shorting Ionis Pharmaceuticals? Ionis Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totaling 9,700,000 shares, an increase of 12.0% from the January 15th total of 8,660,000 shares. Based on an average daily volume of 935,700 shares, the short-interest ratio is currently 10.4 days. Currently, 7.6% of the company's stock are short sold. View Ionis Pharmaceuticals' Short Interest. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the following people: Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65) What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.94%), Sumitomo Mitsui Trust Holdings Inc. (0.56%), Swiss National Bank (0.38%), Sicart Associates LLC (0.30%), Raymond James & Associates (0.25%) and New York State Common Retirement Fund (0.19%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals. Which major investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, Gateway Investment Advisers LLC, Peregrine Capital Management LLC, Andra AP fonden, Trexquant Investment LP, Optimal Asset Management Inc., and International Biotechnology Trust PLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals. Which major investors are buying Ionis Pharmaceuticals stock? IONS stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, WINTON GROUP Ltd, Nisa Investment Advisors LLC, Russell Investments Group Ltd., NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., First Quadrant L P CA, and Swiss National Bank. View insider buying and selling activity for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $53.34. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $7.45 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is www.ionispharma.com. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
